Unlocking Ketogenic Diet for Epilepsy Management

Exploring the Therapeutic Potential of Ketogenic Diets in Epilepsy Management

In a recent analysis published in Nutrients, scholars delved into the intricate mechanisms, efficacy, and adverse effects of ketogenic diet (KD) variations in individuals suffering from epilepsy.

Context

Epilepsy, a neurological disorder, imposes detrimental impacts on the central nervous system, manifesting hepatotoxic and teratogenic effects. Despite the availability of pharmacological interventions, encompassing antiepileptic medications, deep brain stimulation, and surgical procedures, a subset of individuals remains refractory to treatment.

Epilepsy significantly diminishes the quality of life, precipitates cognitive, behavioral, and interpersonal challenges, and heightens the risk of mortality.

Therapeutic interventions for epilepsy aim at seizure management, mitigation of adverse effects, and enhancement of patient well-being. KD stands as a last-resort measure for individuals with drug-resistant seizures.

Know more about the latest epilepsy treatment advances in the upcoming neurology conference at Anaheim, California – Global Neurology Summit 2024

Review Overview

In this comprehensive review, scholars advocate for ketogenic diets as a viable therapeutic avenue for epilepsy.

Variations, Recommendations, Mechanisms, and Adverse Effects of Ketogenic Diets

KD, characterized by a high-fat, low-carbohydrate, and moderate to low protein composition, induces the production of ketone bodies. It adheres to a weight ratio of 4:1 for lipids to nonlipids, with lipids constituting 80% of total caloric intake, proteins 15%, and carbohydrates 5.0%.

For newborns and adolescents, the optimal ratio shifts to 3:1. Indications for KD encompass uncontrolled seizures and drug-resistant epilepsy. Alternative dietary regimens aimed at ameliorating side effects and enhancing patient adherence include the modified Atkins diet (MAD), medium-chain triglyceride (MCT) diet, and low glycemic index therapy (LGIT).

KD exhibits a significant reduction in seizure frequency (SFR), up to 70%, in conditions such as Angelman syndrome, Complex-1 disorders, Dravet syndrome, glucose transporter-1 (GLUT-1) deficiency, Doose syndrome, Febrile infection-associated epilepsy syndrome, Ohtahara syndrome, infantile spasms, super-refractory-type status epilepticus (SRSE), pyruvate dehydrogenase complex (PDC) deficiency, tuberous sclerosis, adenylosuccinate lyase deficiency, and cyclin-dependent kinase-like 5 (CDK). However, KD contraindications pertain to errors associated with lipid and pyruvate metabolisms.

KD elicits neuronal hyperpolarization by attenuating glutamate levels while augmenting neurotransmitters such as norepinephrine, dopamine, serotonin, galanin, neuropeptide Y, gamma-aminobutyric acid (GABA), and brain-derived neurotrophic factor.

Furthermore, KD fosters gut microbiota restoration, activates adenosine triphosphate (ATP)-sensitive potassium currents, enhances mitochondrial oxidative phosphorylation, augments antioxidant production, and inhibits the mammalian target of rapamycin (mTOR) pathway. KD also maintains equilibrium between the brain’s excitatory and inhibitory neurotransmitter systems.

Diminished glucose levels in ketogenic individuals lead to reduced cellular pyruvate/oxaloacetate concentrations, thereby dampening neuronal activity, mitigating seizures, and fortifying neuroprotection.

While KD serves as a management strategy for type 2 diabetes, it may engender side effects such as diarrhea, constipation, nausea, vomiting, dehydration, kidney stone formation, and hepatic impairment.

Alternate diets such as the medium-chain triglyceride diet (MCT), modified Atkins diet (MAD), and low-glycemic-index treatment (LGIT) exhibit higher tolerability; nevertheless, intravenous MCT diets may precipitate hepatic dysfunction, severe iron deficiency, and transient elevations in triglyceride and cholesterol levels.

Research on Ketogenic Diet Efficacy in Epileptic Patients

Randomized clinical trials have juxtaposed the efficacy of standard antiepileptic medication against MAD in managing refractory seizures in children.

MAD demonstrates improvements in both seizure control and behavioral manifestations. Standard ketogenic diet (KD) emerges as a superior initial nutritional intervention for children under two years of age.

MAD exhibits superior efficacy at four weeks compared to conventional KD at 12 weeks, alongside enhanced tolerability. In instances where multiple antiepileptic therapies fail to control infantile seizures, KD surpasses medication alone in effectiveness, thereby reducing the necessity for polypharmacy.

Moreover, the incorporation of ketogenic formulas within the first month of anticonvulsant therapy enhances compliance and reduces seizures more effectively than MAD alone. In adult epilepsy cohorts, KD terminates super-refractory status epilepticus (SRSE) in the majority (73%) of cases, with effects observed within the inaugural week.

Randomized controlled trials corroborate the notion that individuals achieving seizure-free status on the ketogenic diet may persist with it, notwithstanding breakthrough seizures.

Randomized, non-blinded, open-label, parallel, controlled trials evaluating the efficacy and safety of lipid and non-lipid diets in varying ratios to manage refractory pediatric epilepsy among coronary artery disease patients suggest that ketogenic ratios below 4:1 also confer benefits in seizure control.

Management of infantile spasms via the classic KD appears comparably effective to adrenocorticotropic hormone (ACTH) therapy. In addition to reducing seizure frequency, KD elicits advantages such as diminished seizure severity and enhanced cognitive faculties, motivation, mood, and overall quality of life.

Conclusions

Drawing from review insights, KD emerges as an efficacious intervention for drug-resistant and intractable epilepsy syndromes in children and adolescents. It exhibits efficacy in generalized epilepsy albeit to a lesser extent in complex partial seizures.

Principal indications encompass refractory and super-refractory status epilepticus, as well as focal, multifocal, and generalized epilepsy. KD’s anticonvulsant mechanisms encompass glutamate reduction coupled with dopamine, norepinephrine, serotonin, GABA, neuropeptide Y, and brain-derived neurotrophic factor elevation. Additionally, KD modulates gut microbiota and potentiates mitochondrial activity.

While KD may mitigate or eliminate seizure frequency and intensity, patient adherence remains hindered by gastrointestinal side effects and hypercholesterolemia.

Robust, large-scale, placebo-controlled, double-blinded, randomized clinical trials encompassing diverse populations and protracted follow-ups are imperative to furnish high-quality evidence regarding KD’s long-term outcomes and validate its cognitive and developmental ramifications.

For more information: Ketogenic Diet in the Treatment of Epilepsy. Nutrients, https:// doi.org/10.3390/nu16091258